Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION547 in Healthy Volunteers
NCT04934891Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Sep 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hereditary angioedema (HAE) comparing ION547 with Placebo (2 arms). Primary endpoints: Number of Participants With at Least One Treatment-emergent Adverse Event, Maximum Observed Plasma Concentration of ION547 and 5 more. Started Mar 2021; status: completed.
02
Drugs
ION547
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04934891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934891.